They simply would not garner interest imo at this price for a CR, even from the likes of RYD or TM. They would be relying on existing holder interest and that did bugger all in the retail portion of the recent cap raise.
There is only so much "positive deal potential" this and "big player that", however unless it is translating to meaningful revenue, then those deals mean jack. I always think back to Syntonic and the Verizon deal they had. The stock price when gang busters off that, but it actually didn't translate to revenue for the company. They also did a deal with TATA and that didn't eventuate to anything. Until you see the revenue coming in and by meaningful I literally mean tens of millions per year, the interest will be low.
People want this to be a $1+ company again. Well then need $1+ company revenues. Keeping a flat revenue figure each year of circa $20M AUD is not going to all of a sudden change position. The company has sold themselves not on their services side, but on Febridx. Every piece of communication has been on Febridx. So until that starts to make dollars, no one cares.
Hologic's deal could be a game changer for this stock, but that is 18+ months away. People are also forgetting (or being naïve to) the fact that the deal we have signed is to prototype stage only. Post protype, they need clearance for the device which also means trials once the trials are complete, they may need FDA approval again. The benefit is that with Hologic running this, they would have key personnel who know the tick box approach to getting that done with the FDA and if the underlying technology hasn't changed, then there could be the likelihood of FDA providing a swift approval.
Add to My Watchlist
What is My Watchlist?
